loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Gland Pharma has entered into a Manufacturing and Supply Agreement with a global pharma company

ICICIdirect Research 10 Aug 2026 DISCLAIMER

News: Gland Pharma has entered into a Manufacturing and Supply Agreement with a global pharma company for technology transfer, manufacturing and supply of 55 sterile injectable SKUs across three sites. The full-service CDMO mandate covers technology transfer, development, scale-up, validation and commercial manufacturing, with scope for additional products. The portfolio has annualized revenue potential of US$90–100 million upon full commercialization, with technology transfer expected to conclude within two years and revenues to commence from CY29. 

View: The new CDMO agreement is on the heels of the recent deal with Neulands for sterile APIs. Interestingly, the release suggests that the agreement is for both oncology and non-oncology products and hence could be a good margin generator. The deal is expected to fructify from FY30 onwards. During FY26-29E, the management has guided for mid teen growth to be driven by 15-20 new complex products in the injectables space. Gland continues to grow in stature with its 100% injectables offerings both in innovative and generics space.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere